Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunic gets a "positive surprise" from lead asset trial

By: TheNewswire.com

Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).

Vitt describes it as "wonderful data" that came as a "positive surprise."

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  230.28
-1.50 (-0.65%)
AAPL  278.03
-0.75 (-0.27%)
AMD  221.43
+0.01 (0.00%)
BAC  54.56
+0.48 (0.89%)
GOOG  313.70
-7.30 (-2.27%)
META  652.71
+2.58 (0.40%)
MSFT  483.47
+4.91 (1.03%)
NVDA  180.93
-2.85 (-1.55%)
ORCL  198.85
-24.16 (-10.83%)
TSLA  446.89
-4.56 (-1.01%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.